BIOTYPE launches MODAPLEX NRAS Mutation Kit to detect the 15 most critical NRAS driver mutations within 4 hours

Determining NRAS status is crucial for guiding first-line therapy decisions in advanced colorectal cancer (CRC). While NGS technologies are gaining popularity, the number of reported pathogenic mutations in the NRAS gene remains limited.

To bridge this gap, we’re excited to unveil our latest addition to the MODAPLEX Platform: the MODAPLEX NRAS Mutation Kit! This kit detects the 15 most critical NRAS driver mutations in exons 2 and 3 within just 4 hours, with a detection limit ranging from 1 % to 3 %. The NRAS analysis can be seamlessly combined with the upcoming KRAS and BRAF assays, enabling a simple and comprehensive analysis of the sample material.

We're confident that this innovation will elevate molecular testing in CRC and beyond, providing researchers with valuable insights for more effective sample stratification.

Interested in learning more?

Reach out to us at products@biotype.de for more details about our new MODAPLEX NRAS Mutation Kit!